SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scribe Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$19.39−0.69 (-3.44%)
Close on Oct 19, 2026
- Market cap
- $48.01M
- P/E (TTM)
- –
- Dividend yield
- –
Scribe Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Scribe Therapeutics | Industry median |
|---|---|---|
| Market Cap | $48.19M | $166.30M |
| Enterprise Value | $5.19M | $88.19M |
Balance sheet
| Measure | Scribe Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $43.00M | $61.43M |
| Net Cash (Debt) | $43.00M | $15.35M |
| Net Cash Per Share | $17.30 | $0.66 |
| Equity (Book Value) | -$164.85M | $49.09M |
| Book Value Per Share | -$66.33 | $1.37 |
| Tangible Book Value | -$164.85M | $23.52M |
| Working Capital | -$33.59M | $76.81M |
Financial position
| Measure | Scribe Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.57 | 3.34 |
| Quick Ratio | 0.55 | 2.44 |
Shares
| Measure | Scribe Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 2,485,230 | 58,127,000 |
Scores
| Measure | Scribe Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -4.80 | -0.22 |
Calculated by StockData from Scribe Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.